Viewing Oncology Through Mikhail Blagosklonny’s Eyes
Mikhail Blagosklonny is an oncology professor at the Roswell Park cancer institute. He is a scientist whose passion is on the studies of aging and cancer. He attended the first Pavlov Medical University in St. Petersburg from where he attained his MD in internal medicine. He later attained a PhD in experimental medicine and cardiology at the same institution.
In 2002, he was made the associate medical professor in New York medical college in Valhalla. He later moved on to Ordway research institute where he became the lead scientists. His career at Roswell Park cancer institute began in 2009 when he joined as the professor of oncology. He became an excellent professor due to the accumulation of knowledge and the experience he had gathered from all the other places he had worked. View his LinkedIn profile
He has a research interest in bio gerontology, which explains the underlying mechanism of aging. He also focus on anti-aging drugs, targeted cancer therapies that prevent destruction of cells as well as research on cancer in general. He also serves as the chief editor of cell cycle and Oncotarget. He also works as the associate editor for cancer biology and therapy. He also serves in the editorial board of cell death and differentiation editorial board.
Mikhail developed a hypothesis on TOR, which signaled the potential role of cancer as well as aging. He also proposed the use of Rapamycin which is a drug used in the treatment of cancer. His proposal was meant to be used for potential life extension. In fact, he is categorized as a vocal and most passionate researcher when it comes to advocating for the use of rapamycin in life elongation researches. His researches are based on molecular, cellular as well as clinical investigations. As such, it includes tumor suppressors, drug resistance, apoptosis and anticancer therapeutics among others.
The professor also serves as the author of the aging hyper function theory. Mikhail Blagosklonny is also passionate about writing on cyclo therapy and chemotherapeutic engineering. He has especially a very keen interest in oncology and has a strong belief in the possibility of controlling cancer and aging.